


**MILESTONE**  
SCIENTIFIC

**MILESTONE SCIENTIFIC INC.**  
(OTCBB:MLSS)

*The recognized leader in advanced drug delivery injection technologies used by medical and dental professionals worldwide*

<b>Stock Price (08/02/10):</b>	\$1.18	<b>Headquarters:</b>	220 South Orange Avenue, Ste. 102 Livingston, New Jersey 07039
<b>Shares Outstanding:</b>	14.82 Million	<b>Phone:</b>	973-535-2717
<b>Estimated Public Float:</b>	9.83 Million	<b>Fax:</b>	973-535-2829
<b>Market Capitalization:</b>	\$17.48 Million	<b>Web Site:</b>	<a href="http://www.milestonescientific.com">www.milestonescientific.com</a>
<b>52-Week Hi/Lo:</b>	\$0.55/\$1.95		
<b>Fiscal Year End:</b>	Dec 31		



## CORPORATE SUMMARY

Headquartered in Livingston, New Jersey, **Milestone Scientific Inc.** is broadly recognized as a world leading pioneer of highly advanced, computer-controlled, painless injection technologies with commercial applications in a broad spectrum of medical and dental disciplines. Since its founding in 1995, the Company has researched, developed and brought to market a full suite of award-winning, FDA-approved, drug delivery injection instruments that are in use today by medical and dental practitioners in over 25 countries throughout North America, Europe, Asia and Africa.

Milestone is also committed to expanding the use and application of its intellectual property to achieve greater operational efficiencies for the practitioner, improved patient safety, therapeutic adherence and enhanced quality of care. To that end, the Company is pursuing opportunities to team with other leading healthcare technology, biotech and pharmaceutical companies to bring to bear a powerful complement of innovative drug delivery that effectively address a multitude of prevailing healthcare delivery challenges.

Central to Milestone's robust IP portfolio, currently comprised of 25 issued patents, is its FDA-approved *CompuFlo*<sup>®</sup> system for the precise delivery and aspiration of all medicaments. Milestone's patented *CompuFlo* system and *DPS Dynamic Pressure Sensing*<sup>®</sup> technology are revolutionary technologies that are relevant for the entire category of subcutaneous drug delivery injections and fluid aspiration – enabling healthcare practitioners to achieve multiple unique benefits that cannot currently be accomplished with the existing technologies.

The negative side effects possible when using the manual hypodermic syringe are well documented in the medical and dental literature, and include tissue damage, transient or permanent paralysis, subjective pain response, post-operative complications, and the risk of medical emergencies, which in certain circumstances can result in a patient fatality. Patient pain and tissue damage are a direct physical result of a clinician's inability to accurately control a wide range of variables when using the manual syringe.

**In contrast, the technical advantages of the *CompuFlo* system with *DPS Dynamic Pressure Sensing* technology are numerous and dramatic.** They include precise controlling and monitoring of all critical variables during drug delivery, including:

- a true "painless" experience for all injections
- eliminates disruptive injection behavior
- site specific targeting
- controlled needle exit-pressure
- precise flow rate and drug volumes
- patient treatment documentation
- superior ergonomics
- elimination of needle deflection
- advanced tactile needle control
- precision fluid metering

The use of Milestone's technology also empowers the clinician to receive real-time continuous feedback relating to the local tissue conditions during the injection process. This real-time feedback enables the accurate differentiation and identification of specific tissues types and anatomical locations, making subcutaneous drug delivery safer, easier and more effective, thereby fundamentally transforming what formerly was an "art" into a "science."

Recognized as a world leader in advanced computer-controlled injection technologies, Milestone has spent over a decade developing and perfecting its portfolio of technologies that eliminate pain and enable unequalled precision that can be applied to a wide array of subcutaneous injections routinely used in the practice of Medicine and Dentistry. Moreover, none of Milestone's Computer-Controlled Local Anesthetic Delivery (*C-CLAD*<sup>™</sup>) injection products look like a syringe or feel like a syringe, and they perform far better than an antiquated manual syringe, resulting in a much enhanced experience for both the patient and practitioner.

## COMMERCIAL PRODUCTS

Milestone is driven by an underpinning mission to empower medical and dental professionals with effective, painless injection solutions capable of delivering material financial and productivity efficiencies and enhancements, while improving patient comfort, convenience and safety.

### ***CompuMed<sup>®</sup> Instrument***

The *CompuMed<sup>®</sup>* instrument, an FDA-approved Computer-Controlled Local Anesthesia Delivery (C-CLAD) system, was developed by Milestone for local anesthetic delivery applications within the Medical field. Although the *CompuMed* instrument was never actively marketed by the Company, it is currently in use in several niche markets within Medicine today. The *CompuMed* instrument can enable many medical procedures to be conducted with only local anesthesia – procedures that formerly required IV sedation due to the associated pain. It has been reported that dosages of local anesthetic can be significantly reduced when using the *CompuMed* instrument because greater control of drug placement is possible, thus reducing side effects, accelerating recovery times, lowering costs and eliminating potential complications.



The *CompuMed* instrument has gained clinical evidence demonstrating benefits from use in colorectal surgery, podiatry, oncology treatments, dermatology and rhinoplasty. Documented and published medical procedures have been performed for a variety of applications, including removal of benign and malignant hyperplasia, Mohs therapy, sinus surgery, rhinoplasty, hair restoration and transplantation, as well as facial plastic surgical procedures, among others.

### ***CompuDent<sup>®</sup>/The Wand<sup>®</sup> Instrument***

In 1997, Milestone introduced the first generation of its Computer-Controlled Local Anesthetic Delivery (C-CLAD) system, known as *The Wand<sup>®</sup>* (and later rebranded as *CompuDent<sup>®</sup>*). This system is composed of two basic parts, the delivery instrument and the single-use, disposable *Wand* handpiece. *The Wand/CompuDent* instrument provides painless injections for all routine dental treatments including root canals, crowns, fillings and cleanings. With more than 18,000 *CompuDent* instruments sold within four and one half months of its market introduction, **this represented the most successful launch in the history of small equipment sales in U.S. dentistry.**



Moreover, the *CompuDent* instrument has been favorably reviewed in more than 50 peer-reviewed and independent clinical research reports and has been featured in numerous contemporary textbooks on Dentistry. In fact, the *CompuDent* instrument has been prominently featured in the leading text book on dental anesthesia, *Handbook of Local Anesthesia*, authored by Stanley F. Malamed, DDS, current Professor of Anesthesia and Medicine at the University of Southern California School of Dentistry.

### ***STA Single Tooth Anesthesia System<sup>®</sup> Unit***

In late February 2007, Milestone introduced the second generation C-CLAD system based on its patented *CompuFlo* and *DPS Dynamic Pressure Sensing* technologies; and has since received numerous awards and broad industry recognition from key clinical opinion leaders, dental practitioners, trade publications and patients.

Marketed as the *STA Single Tooth Anesthesia System<sup>®</sup>* unit, it provides the dental practitioner with all the benefits previously established using the predicate instrument, *CompuDent*. However, the *STA Single Tooth Anesthesia System* unit includes a significant clinical breakthrough in the field of dental local anesthesia by allowing a specific injection site to be objectively identified for single tooth anesthesia, thus representing another technological “first-for-dentistry.”



Utilizing Milestone’s proprietary *DPS Dynamic Pressure Sensing* technology, audible and visual real-time ‘feedback’ is provided to the clinician to accurately guide and locate a specific injection site by continuously measuring exit-pressure at the tip of the needle. This innovative approach was so remarkable that we were awarded the prestigious Medical Design Excellence Award by Canon Communications in 2008. Milestone continues to obtain broad professional and industry recognition and validation of the *STA Single Tooth Anesthesia System* unit through numerous awards and recognition from key industry leaders and dental publications today.

The Company received FDA 510(k) Pre-market Notification acceptance in August 2006 for the marketing and sale of the instrument, and has since established a global distribution network comprised of leading dental supply companies in the U.S., Canada, China, South Africa and Europe which actively market the *STA Single Tooth Anesthesia System* unit and related disposable handpieces to the worldwide dental industry.

### ***The Wand® Handpiece***

The Wand handpiece is used in conjunction with the *STA Single Tooth Anesthesia System* unit, the CompuDent instrument and the CompuMed instrument. The ergonomically designed and patented handpiece enables all traditional and newer injections to be more comfortable and easier to perform, resulting in improved clinical outcomes for patients. The unique pen-like grasp, in combination with the feather-like weight of *The Wand* handpiece, produces unparalleled tactile control for every injection. Moreover, *The Wand* handpiece allows bi-directional rotation during injection, which prevents needle deflection that occurs with a traditional syringe. A straighter path results in a more accurate injection, meaning fewer missed injections and more rapid onset of medication.



### ***The SafetyWand® Handpiece***

*The SafetyWand* handpiece is the first, patented safety-engineered injection device that conforms to standards while also meeting the clinical needs of dental and medical practitioners. The Federal Needlestick Prevention Act (U.S.) has mandated the use of products with “engineered safety injury protection” to eliminate accidental needle sticks. *The SafetyWand* handpiece was the first patented injection device to be fully compliant with OSHA regulations under the Act.

## **PRODUCT DEVELOPMENT OPPORTUNITIES**

Based on a 2006 independent study, the number of potential applications for the *CompuFlo* system technology stands at more than 700. Due to the sizable number of product development opportunities within the medical arena for the technology, Milestone created an internal review committee to assess and analyze the opportunities in a variety of medical sectors. Consequently, the Company has elected to focus on those medical uses of the *CompuFlo* system which have shown to be most promising for obtaining a return on investment while simultaneously representing new product introductions that will have the greatest impact on patients and the medical profession. Areas of initial interest include developing *CompuFlo*-based injection/aspiration systems for use in Epidurals, Intra-Articular Injections, Self-Administered Injections, Neurosurgery, Ophthalmic surgery and Derma Filler/Cosmetic surgery.

It should be noted that the *CompuFlo* system is embedded in an FDA-approved prototype. This technology is currently commercially available in the *STA Single Tooth Anesthesia System* unit, which is being sold worldwide in the dental market. Over 40 million patient injections have been given with Milestone’s technologies to date. Milestone’s technological innovations have been tried and proven by healthcare providers with over 50 publications validating the efficacy and safety in a variety of medical and dental injection applications. The Company anticipates that any application for a device developed utilizing the *CompuFlo* system will require 510K approval from the FDA, thus minimizing development cost and time to market.

## **RECENT NEWS ANNOUNCEMENTS**

- 07/27/10** Milestone Scientific’s *STA Single Tooth Anesthesia System*® Unit Named as One of *Dentistry Today*’s ‘Top 100 Products’ for Third Consecutive Year
- 05/28/10** Milestone Scientific Announces Results of 2010 Annual Meeting of Stockholders
- 05/13/10** Milestone Scientific Achieves Net Profitability in First Quarter 2010
- 05/04/10** Milestone to Report First Quarter 2010 Results on Wednesday, May 12, 2010
- 05/03/10** Milestone Scientific Receives Notice of Allowance from US Patent and Trademark Office for Computer-Controlled Self-Administration Injection System
- 04/29/10** Milestone Scientific to Present at NIBA 114<sup>th</sup> Investment Conference in San Francisco
- 04/22/10** Milestone Scientific Appoints Dale Johnson as New Director of International Distribution
- 04/20/10** Milestone Scientific Announces Date of 2010 Annual Meeting of Shareholders
- 04/13/10** Milestone Scientific to Exhibit at the 2010 Annual Session of the American Association of Endodontists in San Diego
- 03/26/10** Milestone Scientific Issues Update on New Business Activities in China
- 03/12/10** Milestone Scientific to Present at ROTH Capital Partners’ 22<sup>nd</sup> Annual OC Growth Stock Conference
- 03/11/10** Milestone Scientific Announces 2009 Year End Results
- 03/08/10** Milestone to Report 2009 Year-End Results on Wednesday, March 10, 2010
- 02/22/10** Milestone Scientific Announces Preliminary Fourth Quarter and 2009 Year-End Results
- 02/19/10** Milestone Scientific to Exhibit at Chicago Dental Society’s 145<sup>th</sup> Midwinter Meeting

## CORPORATE LEADERSHIP

<b>Chairman of the Board:</b>	Leslie Bernhard
<b>Chief Executive Officer:</b>	Leonard Osser
<b>Chief Financial Officer:</b>	Joseph D'Agostino
<b>Director of Clinical Affairs:</b>	Mark Hochman, D.D.S.
<b>Director of International &amp; Professional Relations:</b>	Dr. Eugene Casagrande
<b>Director, Engineering &amp; Regulatory Affairs:</b>	Stephen Solomon
<b>Director of International Distribution:</b>	Dale Johnson
<b>Director of Domestic Distribution:</b>	Marvin Terrell

## MARKET MAKERS

Hudson Securities, Inc.	UBS Securities LLC
LaBranche Financial Services, Inc.	The Vertical Trading Group, LLC
Pershing LLC	vFinance Investments, Inc.

## OTHER RELEVANT DATA

<b>Stock Transfer Agent:</b>	Continental Stock Transfer
<b>SEC Counsel:</b>	Morse, Zelnick, Rose & Landers
<b>Auditors:</b>	Holtz Rubenstein Reminick LLP
<b>IR/PR Counsel:</b>	Elite Financial Communications Group, LLC

This publication is an advertisement on behalf of **Milestone Scientific Inc. (hereinafter referred to as "Company")** and may not be construed as investment advice. This advertisement does not provide an analysis of the Company's financial position and is not a solicitation to purchase or sell securities of the Company. Readers should consult with their own independent tax, business and financial advisors with respect to any investment, including any contemplated investment in the advertised Company. All information contained in this advertisement should be independently verified with the advertised Company and by an independent financial analyst. The Publisher, its affiliates, officers, directors, subsidiaries and agents (collectively, "the Publisher") of this advertisement has been contracted by the Company for integrated investor, public and media relations services. From December 2006 through December 2010, compensation to the Publisher will total \$40,000, payable in cash monthly installments and/or restricted common shares. In preparing this advertisement, the Publisher has relied upon information received from the Company, which, although believed to be reliable, cannot be guaranteed. This advertisement is not an endorsement of the Company by the Publisher. The Publisher is not responsible for any claims made by the Company. You should independently investigate and fully understand all risks before investing. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements which are not historical facts contained in this advertisement are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, governmental approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.